Navigation Links
Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands
Date:6/6/2011

CLEVELAND, June 6, 2011 /PRNewswire/ -- Ganeden Biotech announced the sale of its leading Sustenex® and Digestive Advantage® brands of probiotic dietary supplements to Schiff Nutrition International, Inc. for $40 million in cash.  Ganeden will also receive royalties on Schiff products containing GanedenBC30™.  The sale includes the worldwide exclusive rights to use Ganeden's probiotic technology, GanedenBC30™, in the over-the-counter (OTC) and dietary supplement space.  Ganeden and Schiff also intend to collaborate on extending the use of OTC probiotic technologies into new areas of human health.

(Logo: http://photos.prnewswire.com/prnh/20041213/CLM031LOGO)

The capital from the sale and royalties will accelerate the commercialization of Ganeden's remaining high-growth portfolio, including its rapidly expanding food and beverage probiotic ingredients business, its recently launched enLiven™ probiotic yogurt brand, its Ganpro™ line of Direct Fed Microbial feed additives, its clinical-stage entries into the cardiovascular health market, and various feminine health, topical, and cosmetic applications.

Over the past three years, Sustenex® and Digestive Advantage® combined to make Ganeden the largest seller of OTC probiotics in the retail mass market on a unit basis. Consumer loyalty for Ganeden's OTC probiotics, as measured by repeat purchase rate, grew to be the second highest among the top 50 brands of OTC gastrointestinal products sold in the United States.

"After achieving a leading market position with our Sustenex® and Digestive Advantage® brands with a very limited marketing spend, we believed it was the right time to sell these brands to a partner that will provide incremental marketing support, which will substantially increase the number of consumers who will benefit from the daily use of our probiotics," said Andrew Lefkowitz, Ganeden's President and CEO.

"Although Ganeden has already been awarded over 100 patents around the world and published 13 studies in peer-reviewed journals, this transaction will also give us the capital needed to further substantiate the efficacy of GanedenBC30™ in a broad range of human and animal health applications through greater focus on our scientific expertise," Lefkowitz added.

About Ganeden Biotech

Ganeden Biotech is a Cleveland, Ohio, based company that markets enLiven™ probiotic yogurt in Walmart stores nationally and licenses its patented strain of probiotic bacteria, GanedenBC30™, for use in branded food and beverage applications. Ganeden also markets its Ganpro™ brand of direct fed microbial as an alternative to traditional antibiotic use. Ganeden licenses its technology directly and through select distributors such as Glanbia Nutrition, PL Thomas, Sochim, and Pathway International.  GanedenBC30™ is also known as Bacillus coagulans GBI-30, PTA-6086.  Clinical trials show that GanedenBC30™ is effective in irritable bowel syndrome (IBS), intestinal gas, and in boosting the immune system against cold and flu viruses.  GanedenBC30™ is currently being studied in IBS and depression by researchers at the Massachusetts General Hospital and in HIV infection by researchers at the AIDS Healthcare foundation.  For more information, visit www.GanedenLabs.com.


'/>"/>
SOURCE Ganeden Biotech
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
2. Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener
3. Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology
4. Ganeden Biotech Introduces GanPro(TM) Direct-Fed Microbial for Livestock
5. Ganeden Biotech Introduces the First Probiotic Thin Strip
6. Ganeden Biotech Granted 100th Probiotic Patent
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Yongye Biotechnology International Retains CCG Investor Relations
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):